Doximity's 31% Jump Looks Real: Has the Bull Case Gotten Stronger-or Just Louder?

Why Doximity's post-earnings surge changed the debate

Doximity's about 33% surge in the first full session after its Q1 2027 report made the bull case more compelling-and much less forgiving. The market suddenly had to treat the stock as more than a sleepy digital-health name: it now had to explain how much of the move reflected a profitable platform adding a credible AI story.

Profitability held up while AI investment continued

The quarter gave bulls real substance. Doximity produced roughly $156.6 million of revenue, up about 7%, while holding a 48% adjusted EBITDA margin. In plain English, the company appeared to keep its high-margin model intact while continuing to invest in AI.

But the setup also became harder to ignore. Net income fell about 54%, even as management raised full year revenue guidance and said AI search is generating 10 times the revenue it costs to run. The upside case is no longer just that AI could help. It is now: show us the payback quickly.

Why the market now wants proof, not just a pitch

The raised forecast still looks conservative because analysts believe it does not include a material AI contribution. That leaves the stock in a transitional zone: the base business looks healthier than feared, but any further rerating depends on AI becoming a real revenue contributor, not just a compelling narrative.

If monetization accelerates, today's price may still look early. If it stalls, the debate will turn back toward whether the move reflected lasting value or mostly a short squeeze on an otherwise solid quarter.

Doximity's adoption metrics matter more than the headline rally

The next step in the thesis is straightforward: AI has to generate revenue from real usage inside Doximity's network, not just headlines.

Distribution plus repeat use is the real signal

The cleanest signal is adoption. In Doximity's most recent quarter before Q1 2027, over 800,000 active prescribers were using its workflow tools, and nearly half of those providers used clinical AI. Prompts per user also nearly doubled from January to April. That combination matters because distribution alone is not enough; repeat usage is what turns a feature into a monetizable product.

A flashy AI tool can look impressive on a slide, but if clinicians are already using it inside their normal workflow, each additional interaction has a better chance of supporting ads, pharma sponsorship, or paid features. That is the higher-margin revenue stream investors care about.

Product quality is part of the monetization path

This adoption story also appears to rest on practical utility, not just marketing. Management said its clinical AI posted a 4.8% error rate versus 13.6% for Anthropic's model in physician-focused testing. Bears can fairly argue that one comparison does not prove market leadership. Still, for physicians, accuracy is central to trust, and trust is central to adoption.

Management also said AI search is earning more than 10 times per search in revenue than it costs. That is useful early evidence on unit economics, but it is still early. Just as important, analysts believe that payback is not yet baked into the raised full-year forecast.

• Bulls see a large built-in audience, rising usage, and a plausible accuracy advantage.
• Bears see one quarter of strong attention and argue that scale revenue has not shown up yet.

My view: the bull case is stronger, but only if the next few quarters turn these adoption signals into repeat demand and reported revenue.

The stock's rerating may still be partly mechanical

What the market may still be underestimating is how much of the move was driven by shorts covering, rather than by a fully settled change in fundamental demand. Doximity went into earnings with 17% of float sold short, so part of the rerating was mechanical. Once a crowded short position unwinds, price can jump before the long-term owner base has fully reloaded on fundamentals. That makes the setup more interesting, not automatically safer.

What is already priced in-and what may not be

The market clearly rewarded a better base business: Doximity delivered a solid first quarter, held its margin, and management raised full-year revenue guidance. But the important subtlety is what remains outside that forecast. Analysts believe the company's raised FY27 guidance of $671 million to $681 million still does not reflect a meaningful AI contribution. In other words, bulls are not yet paying for the full AI payoff; they are paying for the chance that it arrives.

That is a real opportunity, but it is also the trap. A stock can rise on better guidance and still stall if the next leg of growth remains a promise rather than a booked driver.

What could still go wrong

Bears have a fair argument. Doximity still has to overcome market discomfort with recent net-income softness and prove that AI monetization can scale beyond early unit-economics commentary. Management said AI search is earning more than 10 times per search in revenue than it costs, which is encouraging. He also said it is early days. That matters: positive early math is not the same as durable scale.

There is also a timing risk. Some bulls are looking for AI revenue to become a more visible growth driver in the third quarter. If that timeline slips, sentiment can cool even if the underlying business remains healthy.

Has the bull case actually changed?

Yes-but only in a specific way. Doximity no longer needs to prove it can protect profit while funding AI; it already did that with a 48% adjusted EBITDA margin. What changed is that the monetization path looks more tangible than it did a few weeks ago, thanks to new partnerships with Aledade and Photon, prompts per user nearly doubling, and management's claim that AI search is earning more than 10 times per search in revenue than it costs. That sharpens the thesis, but it does not remove execution risk.

The reason is simple: investors still do not have the payoff in reported numbers. Management raised full-year revenue guidance, but analysts believe that forecast still does not include a material AI contribution. So the stock is getting a better bull case, while still being asked to pay for potential before the benefit shows up more clearly in cash flow.

What to watch next

• Whether AI revenue moves from promise to a meaningful growth driver in the third quarter
• Whether the active prescriber base keeps growing and prompts per user stay strong
• Whether AI search's early unit economics translate into rising usage and pricing power
• Whether the latest guidance continues to look like a floor rather than a ceiling

If the next few reports turn early adoption into reported growth, the move may still look early. If not, the debate will shift back toward how much of the rally was substance and how much was sentiment accelerating ahead of proof.